Point72 Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-221,592
| Closed | -$44.2M | – | 3885 |
|
|
2025
Q4 | $44.2M | Buy |
+221,592
| New | +$40.2M | 0.05% | 463 |
|
|
2025
Q3 | – | Sell |
-236,408
| Closed | -$35.9M | – | 2370 |
|
|
2025
Q2 | $35.9M | Buy |
+236,408
| New | +$31.5M | 0.07% | 321 |
|
|
2024
Q1 | – | Sell |
-368,984
| Closed | -$87.2M | – | 2257 |
|
|
2023
Q4 | $87.2M | Buy |
368,984
+307,398
| +499% | +$60.5M | 0.21% | 111 |
|
|
2023
Q3 | $12.1M | Sell |
61,586
-193,592
| -76% | -$39.7M | 0.04% | 580 |
|
|
2023
Q2 | $53.7M | Buy |
+255,178
| New | +$50.8M | 0.16% | 168 |
|
|
2022
Q4 | – | Sell |
-211,900
| Closed | -$41.7M | – | 1551 |
|
|
2022
Q3 | $41.7M | Buy |
211,900
+197,387
| +1,360% | +$42.6M | 0.17% | 163 |
|
|
2022
Q2 | $3.1M | Sell |
14,513
-64,148
| -82% | -$15.7M | 0.01% | 823 |
|
|
2022
Q1 | $22.3M | Buy |
78,661
+1,761
| +2% | +$543K | 0.09% | 301 |
|
|
2021
Q4 | $29M | Buy |
76,900
+64,006
| +496% | +$24.9M | 0.12% | 258 |
|
|
2021
Q3 | $5.32M | Sell |
12,894
-32,587
| -72% | -$13.5M | 0.02% | 648 |
|
|
2021
Q2 | $16.8M | Sell |
45,481
-108,541
| -70% | -$36.2M | 0.08% | 326 |
|
|
2021
Q1 | $44.6M | Buy |
154,022
+83,770
| +119% | +$23.3M | 0.21% | 124 |
|
|
2020
Q4 | $17.6M | Buy |
70,252
+16,780
| +31% | +$4M | 0.09% | 307 |
|
|
2020
Q3 | $12.1M | Buy |
+53,472
| New | +$11.1M | 0.06% | 370 |
|
|
2020
Q2 | – | Sell |
-260,500
| Closed | -$32.9M | – | 842 |
|
|
2020
Q1 | $32.9M | Buy |
260,500
+103,628
| +66% | +$15.5M | 0.27% | 106 |
|
|
2019
Q4 | $24M | Buy |
156,872
+144,949
| +1,216% | +$20.1M | 0.13% | 232 |
|
|
2019
Q3 | $1.58M | Buy |
11,923
+11,423
| +2,285% | +$1.53M | 0.01% | 623 |
|
|
2019
Q2 | $71K | Buy |
+500
| New | +$67.8K | ﹤0.01% | 1103 |
|
|
2019
Q1 | – | Sell |
-307,600
| Closed | -$34.8M | – | 1049 |
|
|
2018
Q4 | $34.8M | Buy |
+307,600
| New | +$38.5M | 0.17% | 158 |
|
|
2016
Q2 | – | Sell |
-104,600
| Closed | -$7.94M | – | 741 |
|
|
2016
Q1 | $7.94M | Sell |
104,600
-24,900
| -19% | -$1.84M | 0.06% | 335 |
|
|
2015
Q4 | $10.4M | Buy |
+129,500
| New | +$9.34M | 0.09% | 276 |
|
|
2015
Q3 | – | Sell |
-185,000
| Closed | -$13M | – | 784 |
|
|
2015
Q2 | $13M | Buy |
+185,000
| New | +$13.7M | 0.09% | 275 |
|
|
2015
Q1 | – | Sell |
-25,700
| Closed | -$1.64M | – | 700 |
|
|
2014
Q4 | $1.64M | Sell |
25,700
-105,700
| -80% | -$6.63M | 0.01% | 568 |
|
|
2014
Q3 | $7.85M | Buy |
+131,400
| New | +$7.52M | 0.06% | 321 |
|
Other funds holding CRL
VCM
VPM
Point72 Asset Management's CRL Position: Q1 2026 in Review
Point72 Asset Management sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 221,592 shares — an estimated $44.2M sold.
Point72 Asset Management first reported a position in CRL in Q3 2014 and held it in 24 quarters. The position peaked at $87.2M in Q4 2023. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Point72 Asset Management reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
- Point72 Asset Management sold 221,592 Charles River Laboratories shares in Q1 2026, an estimated $44.2M.
- Point72 Asset Management first reported a position in Charles River Laboratories in Q3 2014 and held it in 24 quarters.
- Point72 Asset Management's Charles River Laboratories position peaked at $87.2M in Q4 2023.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.